Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C] AZD0530, Saracatinib
AZD0530 · 4 trials · 7 indications
Number of responders (complete (CR) or partial (PR) responders). CR = disappearance of all target lesions PR = 30% decrease in the sum of the longest diamete. Analysis was based on August 31, 2009 data cut-off , and was performed with patients who had measurable disease and received AZD0530 175mg or Placebo 175mg.
Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
| Arm | Type | Description |
|---|---|---|
| Active Comparator | ACTIVE_COMPARATOR | carboplatin plus paclitaxel |
| 2 | EXPERIMENTAL | AZD0530 in combination with carboplatin plus paclitaxel |
| AZD0530 175 mg | EXPERIMENTAL | AZD0530 (saracatinib) 175 mg once daily |
| Zoledronic Acid 4 mg | EXPERIMENTAL | Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period |
| 1 | EXPERIMENTAL | AZD0530 |
| 3 | EXPERIMENTAL | AZD0530 + Carboplatin + Paclitaxel |
| Name | Type | Description |
|---|---|---|
| AZD0530 | DRUG | oral once daily dose |
| Carboplatin | DRUG | intravenous injection |
| Paclitaxel | DRUG | intravenous infusion |
| Zoledronic Acid | DRUG | - |
Inclusion Criteria: * Have a diagnosis of advanced ovarian cancer * Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy * Estimated life expectancy of more than 12 weeks Exclusion Criteria: * Central Ner...
Top 20 of 87 competitors
AZD0530 is an investigational small molecule developed by AstraZeneca PLC for oncology indications. It has been studied in breast cancer, ovarian cancer, prostate cancer, solid tumors, and other neoplasms. The compound is also referred to as [14C] AZD0530 in some study contexts. It remains in clinical development and is not described as an approved therapy.
AZD0530 has been evaluated in a Phase 2 study of patients with advanced ovarian cancer, identified as NCT00610714. That trial enrolled 211 female participants aged 18 and older across multiple countries including Canada, the United Kingdom, Spain, and others. The study is completed. AZD0530 is investigational and not an approved treatment for ovarian cancer.
AstraZeneca PLC develops AZD0530. The company trades under the ticker AZN. AstraZeneca sponsored the clinical studies of AZD0530 in solid tumors, ovarian cancer, breast cancer, and prostate cancer with metastatic bone disease.
AZD0530 has reached Phase 2 clinical development. Completed studies include Phase 2 trials in advanced ovarian cancer and in breast and prostate cancer patients with metastatic bone disease, along with Phase 1 studies in solid tumors. AZD0530 is investigational and is not described as an FDA-approved product.
Completed AZD0530 trials include NCT00610714, a Phase 2 study in advanced ovarian cancer with 211 patients, NCT00558272, a Phase 2 study in breast and prostate cancer with metastatic bone disease, NCT00704366, a Phase 1 solid tumor study in Japan, and NCT00496028, a Phase 1 solid tumor study in Europe.
Yes, [14C] AZD0530 is an alternative name for AZD0530, referring to the carbon-14 labeled form of the compound used in study settings. Both names refer to the same AstraZeneca small molecule being investigated in oncology indications including breast cancer, ovarian cancer, and solid tumors.